You will need to register to participate. The online registration can be found here: HCP Portal
ALLY® Refill Report Program
You can use the following resources in ALLY to help your patients stay on track with CAYSTON
SMART ALERTS
ALLY provides communication options and alerts to help patients with the following:
- Overdue refills
- Reimbursement issues
Alerts will be identifiable on the ALLY portal "My Patients" page and sent via email to the primary ALLY contact.
CAYSTON ACCESS PROGRAM® (CAP)
With e-enrollment in ALLY, you can:
- Enroll your patients into CAP
- Send their CAYSTON prescription directly to CAP instead of faxing
PATIENT INFORMATION
ALLY’s online portal stores prescription and refill data, which is updated regularly. You will be able to use ALLY to view important information such as:
- Insurance details
- Dispensed data
- CAP status updates
- CAP documentation
HOW YOU CAN PARTICIPATE IN THIS PROGRAM
ALLY REFILL REPORT PROGRAM
Important Safety Information and Indication
Contraindications
CAYSTON is contraindicated in patients with a known allergy to aztreonam.
INDICATION
CAYSTON is indicated to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (Pa). Safety and effectiveness have not been established in pediatric patients below the age of 7 years, patients with FEV1 <25% or >75% predicted, or patients colonized with Burkholderia cepacia.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of CAYSTON and other antibacterial drugs, CAYSTON should be used only to treat patients with CF known to have Pa in the lungs.
Warnings and Precautions
-
Allergic Reactions: Severe allergic reactions have been reported following administration of aztreonam for injection to patients with no known history of exposure to aztreonam. In addition, allergic reaction with facial rash, facial swelling, and throat tightness was reported with CAYSTON in clinical trials. If an allergic reaction occurs, stop administration of CAYSTON and initiate treatment as appropriate. Caution is advised when administering CAYSTON to patients if they have a history of allergy to beta-lactam antibiotics, such as penicillins, cephalosporins, and/or carbapenems, since cross-reactivity may occur.
-
Bronchospasm: Bronchospasm is a complication associated with nebulized therapies, including CAYSTON. Reduction of 15% or more in forced expiratory volume in 1 second (FEV1) immediately following administration of study medication after pretreatment with a bronchodilator was observed in 3% of patients treated with CAYSTON.
-
Decreases in FEV1 After 28-Day Treatment Cycle: In clinical trials, patients with increases in FEV1 during a 28-day course of CAYSTON were sometimes treated for pulmonary exacerbations when FEV1 declined after the treatment period. Healthcare providers should consider a patient’s baseline FEV1 measured prior to CAYSTON therapy and the presence of other symptoms when evaluating whether post-treatment changes in FEV1 are caused by a pulmonary exacerbation.
-
Development of Drug-Resistant Bacteria: Prescribing CAYSTON in the absence of known Pa infection in patients with CF is unlikely to provide benefit and increases the risk of development of drug-resistant bacteria.
Adverse Reactions
-
Adverse reactions (>5%) in CAYSTON patients were cough, nasal congestion, wheezing, pharyngolaryngeal pain, pyrexia, chest discomfort, abdominal pain, and vomiting. Adverse reactions reported (<5%) in CAYSTON patients were bronchospasm and rash.
Indication
CAYSTON is indicated to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa (Pa). Safety and effectiveness have not been established in pediatric patients below the age of 7 years, patients with FEV1 <25% or >75% predicted, or patients colonized with Burkholderia cepacia.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of CAYSTON and other antibacterial drugs, CAYSTON should be used only to treat patients with CF known to have Pa in the lungs.
Please click here to see full Prescribing Information.
Important Safety Information
×
How you can participate in this program
By enrolling in ALLY, you will receive the CAYSTON refill reports for patients who are enrolled in CAP.
1. Opt In
2. Encourage Your Patients to Enroll
The Cayston Access Program will send you a list of your patients who are already enrolled in the program.
If your patient is not already enrolled in the Cayston Access Program, patients can enroll at any time by calling 1-877-7CAYSTON. Enrollment forms can be found below.
3. Receive Reports
Reports will be available through a secure online portal accessible at any time or by faxed report sent monthly.
A personalized refill report will be mailed on a quarterly basis to each patient enrolled in the Cayston Access Program.
Data available through online healthcare provider portal
- If you choose this option, the Cayston Access Program will provide you with access to a secure online healthcare provider portal
- The online portal will provide access to refill history data for all your patients who are enrolled in the Cayston Access Program
Data available through faxed refill report
- Each refill report includes refill history data on an individual patient enrolled in the Cayston Access Program. If you choose this option, reports for each patient will be faxed to you on a monthly basis
Ways to help patients stay on treatment as prescribed
- Use the refill reports to help facilitate a discussion with your patients and uncover issues they may be facing with taking their treatments
- Remind patients why they are taking CAYSTON and of their treatment goals
- Review the clinical study data regarding efficacy and safety
- Provide patients with the CAYSTON Refill Calendar to review start and end dates for their prescribed CAYSTON courses and remind them about ordering refills
Cayston Access Program Forms
For enrollment with CAP, complete the following enrollment form with your patients. Fax the enrollment form to the Cayston Access Program at 1-877-550-1705.
